In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

CompletedOBSERVATIONAL

Enrollment

160

Participants

Timeline

Start Date

September 13, 2020

Primary Completion Date

September 14, 2024

Study Completion Date

September 14, 2024

Conditions

Glioblastoma

Trial Locations (5)

Centre Georges François Leclerc, Dijon

CHU de DIJON, Dijon

Azienda Ospedaliera Università di Padova, Padua

CHU de Nantes, Saint-Herblain

Università di Florence, Florence

All Listed Sponsors

lead

Centre Georges Francois Leclerc

OTHER

NCT03481231 - In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma | Biotech Hunter | Biotech Hunter